PNC-27 vs Tirzepatide
Side-by-side comparison of key properties, dosing, and research.
Immune Support
PNC-27GLP-1 / Weight Loss Agonists
Tirzepatide- Summary
- PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
- Half-Life
- Not well established; estimated minutes to hours
- ~5 days
- Admin Route
- Intravenous (research), Intraperitoneal (research)
- SubQ
- Research
- —
- —
- Typical Dose
- Not established for humans; research doses vary by cell line and model
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- Frequency
- Not established for human use
- Once weekly, subcutaneous
- Key Benefits
- Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
- Spares normal cells lacking surface HDM2 expression
- Membranolytic mechanism bypasses intracellular resistance pathways
- Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
- Potential for combination with conventional chemotherapy
- Novel non-genotoxic anticancer mechanism
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
- Side Effects
- Limited human clinical data; largely in vitro and animal studies
- Potential immunogenic reactions (foreign peptide)
- Systemic toxicity at high doses not well characterized
- Unknown interactions with current chemotherapy agents
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- +3 more
- Stacks With
- —
- —